Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases

Michela SilacciCovagen AG; one of the Janssen Pharmaceutical Companies of Johnson & Johnson; Wagistrasse 25, 8952Schlieren, SwitzerlandCorrespondence[email protected]

Wibke LembkeCovagen AG; one of the Janssen Pharmaceutical Companies of Johnson & Johnson; Wagistrasse 25, 8952Schlieren, Switzerland

Richard WoodsCovagen AG; one of the Janssen Pharmaceutical Companies of Johnson & Johnson; Wagistrasse 25, 8952Schlieren, Switzerland

Isabella Attinger-TollerCovagen AG; one of the Janssen Pharmaceutical Companies of Johnson & Johnson; Wagistrasse 25, 8952Schlieren, Switzerland

Nadja Baenziger-ToblerCovagen AG; one of the Janssen Pharmaceutical Companies of Johnson & Johnson; Wagistrasse 25, 8952Schlieren, Switzerland

Sarah BateyCovagen AG; one of the Janssen Pharmaceutical Companies of Johnson & Johnson; Wagistrasse 25, 8952Schlieren, Switzerland

Roger SantimariaCovagen AG; one of the Janssen Pharmaceutical Companies of Johnson & Johnson; Wagistrasse 25, 8952Schlieren, Switzerland

Ulrike von der BeyCovagen AG; one of the Janssen Pharmaceutical Companies of Johnson & Johnson; Wagistrasse 25, 8952Schlieren, Switzerland

Susann Koenig-FriedrichCovagen AG; one of the Janssen Pharmaceutical Companies of Johnson & Johnson; Wagistrasse 25, 8952Schlieren, Switzerland

Wenjuan ZhaCovagen AG; one of the Janssen Pharmaceutical Companies of Johnson & Johnson; Wagistrasse 25, 8952Schlieren, Switzerland

Bernd SchlerethCovagen AG; one of the Janssen Pharmaceutical Companies of Johnson & Johnson; Wagistrasse 25, 8952Schlieren, Switzerland

Mathias LocherCovagen AG; one of the Janssen Pharmaceutical Companies of Johnson & Johnson; Wagistrasse 25, 8952Schlieren, Switzerland

Julian BertschingerCovagen AG; one of the Janssen Pharmaceutical Companies of Johnson & Johnson; Wagistrasse 25, 8952Schlieren, Switzerland

Dragan GrabulovskiCovagen AG; one of the Janssen Pharmaceutical Companies of Johnson & Johnson; Wagistrasse 25, 8952Schlieren, Switzerland

show all

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases

Silacci et al Supplemental Data

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases

Silacci et al Supplemental Data

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date